Life Sciences Investigations: Doj and Oig Enforcement Defense Strategy

A CID imposes an immediate legal obligation to preserve all documents, data, and communications responsive to the demand, and destruction of relevant materials after receipt constitutes obstruction that independently compounds the company's legal exposure. White collar investigations counsel must identify all documents protected by attorney-client privilege or work product doctrine before any production commences, since privilege waiver in a government investigation can expose communications the company would otherwise have the right to withhold. The government's theory of the case, inferred from the categories of documents requested in the CID, must be assessed before counsel determines the appropriate production scope and response posture.

A qui tam complaint under the False Claims Act is filed under seal and initially served only on the government, which investigates the allegations for sixty days or longer before deciding whether to intervene in the litigation. Defense counsel must immediately assess the relator's likely identity and the factual basis of the alleged fraud, since the relator possesses information the company may not know has been disclosed to the government. Whistleblower litigation counsel must evaluate whether the alleged conduct falls within the government's enforcement priorities and whether the facts alleged, if true, would satisfy the FCA's falsity and materiality requirements.

The combined financial exposure from a False Claims Act violation and an Anti-Kickback Statute enforcement action can eliminate a life sciences company's accumulated profitability across multiple product lines in a single settlement. Understanding the specific penalty structure and the factors that influence final settlement amounts is essential to evaluating whether early cooperation or vigorous defense better serves the company's long-term interests.

The Anti-Kickback Statute imposes criminal penalties of up to ten years imprisonment per violation and civil monetary penalties of fifteen thousand dollars per violation, and each individual kickback transaction constitutes a separate violation. When a false claim submitted to Medicare or Medicaid was caused by an AKS violation, the False Claims Act's treble damages provision multiplies the total alleged overpayment by three, and each fraudulent claim carries an additional civil penalty now exceeding twenty-seven thousand dollars. Healthcare fraud investigations resulting in DOJ settlement also frequently require the company to enter a Corporate Integrity Agreement as a condition of continued participation in federal healthcare programs.

Exclusion from participation in Medicare, Medicaid, and other federal healthcare programs is the most severe non-criminal consequence of a life sciences enforcement action and is administered by the OIG under 42 U.S.C. Section 1320a-7. Mandatory exclusion applies automatically upon conviction of a healthcare fraud offense, patient abuse, or controlled substance felony, regardless of whether the convicted entity wishes to continue participating in federal programs. Suspension and debarment counsel representing a company facing exclusion must engage the OIG at the earliest stage to present factors mitigating against exclusion, since the agency has discretion to consider the adequacy of the company's compliance program and cooperation in its determination.

Attorney-client privilege covers communications between lawyers and their clients made for the purpose of obtaining legal advice, and the privilege belongs to the company rather than to individual employees. Government investigators frequently ask company employees to describe communications with inside or outside counsel, and each such inquiry must be managed through defense counsel rather than through direct employee response. Investigations, compliance and ethics counsel must establish a clear privilege log for every document reviewed and a protocol for which attorney communications may be shared with investigators and which are withheld.

Criminal prosecution under the Anti-Kickback Statute requires the government to prove that the defendant knew the conduct was unlawful, a specific intent standard that differs from the knowing standard applicable to civil FCA liability. A company that received a written legal opinion from qualified healthcare regulatory counsel supporting the legality of its commercial arrangement at the time the arrangement was implemented has a strong scienter defense, even if that opinion is subsequently determined to have been incorrect. Federal criminal defense counsel must build the factual record of the company's legal advice and compliance training to support the argument that any violation was not willful and does not warrant criminal prosecution.

The OIG's Provider Self-Disclosure Protocol and the DOJ's voluntary disclosure guidance specify that companies that self-report violations, cooperate fully, and remediate identified misconduct will receive meaningfully more favorable financial resolution terms than those that wait for the government to develop the case independently. Early voluntary disclosure before the investigation is complete can result in a single-damages settlement, exclusion waivers rather than mandatory exclusion, and resolution without criminal prosecution of the entity. Anti-corruption investigations counsel advising on voluntary disclosure must confirm that the protocol selected matches the agency to which disclosure is being made, since OIG, DOJ, and FDA each have separate self-disclosure programs with different procedural requirements.

A Corporate Integrity Agreement typically requires the company to retain an independent review organization to audit claims, arrangements, and compliance activities for a five-year term, and the scope of the IRO's access and reporting obligations determines the degree to which CIA compliance constrains day-to-day operations. CIA provisions requiring pre-approval of marketing arrangements and speaker programs before implementation represent the most burdensome obligations, and counsel must negotiate specific definitions and approval timelines that preserve the company's ability to conduct normal commercial activities. Healthcare fraud defense counsel experienced in CIA negotiations understands that the OIG accepts narrowed monitoring protocols when the company's compliance program demonstrates a genuine cultural commitment to legal compliance rather than a paper program created solely for negotiation purposes.